Company intelligence / Profile preview

Arana Therapeutics

Macquarie Park, NSW, Australiarctech.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Arana advanced an anti-TNF antibody (ART621) into Phase III clinical trials before being acquired by Cephalon in 2009. The company completed a Phase I trial of ART621 in 2007 showing it was well tolerated in healthy volunteers, and began Phase II trials for psoriasis and rheumatoid arthritis in 2008.

Therapeutic areas: GastroenterologyOphthalmologyImmunologyDermatologyOncologyInfectious Diseases
Modalities: AntibodiesDomain antibodiesPeptides
Industry: Biotech

Drug pipeline

5 assets

BB-401

Phase 1

Indications: Head and neck squamous cell carcinoma (HNSCC)

4 more assets in the full pipeline.

Request access →

Partnerships

Kyowa Hakko-Kirin

Beyond the preview

Go deeper on Arana Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arana Therapeutics.

Explore the full profile